SLRN | Acelyrin, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.11 - 3.25
52 Week Range	3.11 - 8.89
Beta	0.86
Implied Volatility	202.22%
IV Rank	64.09%
Day's Volume	902,556
Average Volume	639,692
Shares Outstanding	100,325,570
Market Cap	316,025,546
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-05-04

Valuation
Profitability
Growth
Health
P/E Ratio	-1.28
Forward P/E Ratio	N/A
EPS	-2.46
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	135
Country	USA
Website	SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

*Chart delayed

Analyzing fundamentals for SLRN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SLRN Fundamentals page.

Watching at SLRN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SLRN Technicals page.